Cirmtuzumab-Imbruvica Yields ‘Encouraging’ Response Rates Against Mantle Cell Lymphoma, Ongoing Trial Shows
News
Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the ... Read more